Analysis of serum biomarkers (BM) in patients (pts) from a phase 3 study of lenvatinib (LEN) vs sorafenib (SOR) as first-line treatment for unresectable hepatocellular carcinoma (uHCC)

Richard S. Finn; Masatoshi Kudo; Ann‐Lii Cheng; Lucjan Wyrwicz; RKC Ngan; J.-F. Blanc; Ari David Baron; Arndt Vogel; Masafumi Ikeda; Fabio Piscaglia; Kwang–Hyub Han; Shukui Qin; Yukinori Minoshima; Yasuhiro Funahashi; Min Ren; Ryo Dairiki; Perminder S. Sachdev; Toshiyuki Tamai; Corina E. Dutcus; T.R. Jeffry Evans

doi:10.1093/annonc/mdx440.022

Article2017

Phase III trial of lenvatinib (LEN) vs sorafenib (SOR) in first-line treatment of patients (pts) with unresectable hepatocellular carcinoma (uHCC).

Ann‐Lii Cheng, Richard S. Finn, Shukui Qin, Kwang–Hyub Han, Kenji Ikeda, Fabio Piscaglia, Ari David Baron, Joong‐Won Park, Guohong Han, Jacek Jassem, Jean–Frédéric Blanc, Arndt Vogel, Д. В. Комов, T.R. Jeffry Evans, Carlos López, Corina E. Dutcus, Min Ren, Silvija Kraljevic, Toshiyuki Tamai, Masatoshi Kudo

Article2018

Final analysis of serum biomarkers in patients (pts) from the phase III study of lenvatinib (LEN) vs sorafenib (SOR) in unresectable hepatocellular carcinoma (uHCC) [REFLECT]

Richard S. Finn, Masatoshi Kudo, Ann‐Lii Cheng, Lucjan Wyrwicz, RKC Ngan, J.-F. Blanc, Ari David Baron, Arndt Vogel, Masafumi Ikeda, Fabio Piscaglia, Kwang–Hyub Han, Shukui Qin, Yukinori Minoshima, Michio Kanekiyo, Min Ren, Ryo Dairiki, Toshiyuki Tamai, Corina E. Dutcus, Yasuhiro Funahashi, T.R. Jeffry Evans

Article2024

Nivolumab (NIVO) plus ipilimumab (IPI) vs lenvatinib (LEN) or sorafenib (SOR) as first-line treatment for unresectable hepatocellular carcinoma (uHCC): First results from CheckMate 9DW.

Peter R. Galle, Thomas Decaens, Masatoshi Kudo, Shukui Qin, Leonardo Goliatt, Bruno Sangro, Hatim Karachiwala, Joong‐Won Park, Edward Gane, Matthias Pinter, David Tai, Armando Santoro, Gonzalo Pizarro, Chang‐Fang Chiu, Michael Schenker, Aiwu Ruth He, Qi Wang, Caitlyn Stromko, Joseph Hreiki, Thomas Yau

Article2018

Independent imaging review (IIR) results in a phase 3 trial of lenvatinib (LEN) versus sorafenib (SOR) in first-line treatment of patients (pts) with unresectable hepatocellular carcinoma (uHCC).

Riccardo Lencioni, Masatoshi Kudo, Richard S. Finn, Shukui Qin, Kwang–Hyub Han, Kenji Ikeda, Ann‐Lii Cheng, Fabio Piscaglia, Guohong Han, Masafumi Ikeda, Krzysztof Simon, Д. В. Комов, Xuenong Ouyang, T.R. Jeffry Evans, Max W. Sung, Terri A. Binder, Andrew Damon, Silvija Kraljevic, Min Ren, Baek‐Yeol Ryoo

Article2024

ctDNA analysis of patients (pts) with unresectable hepatocellular carcinoma (uHCC) treated with lenvatinib (LEN) or sorafenib (SOR) as 1L therapy.

T.R. Jeffry Evans, Masatoshi Kudo, Ann‐Lii Cheng, Lucjan Wyrwicz, Roger K.C. Ngan, Jean-Frédéric Blanc, Ari David Baron, Arndt Vogel, Masafumi Ikeda, Fabio Piscaglia, Shukui Qin, Taisuke Hoshi, Ryuji Tamaki, Yasuhiro Funahashi, Chinyere E. Okpara, Koji Sagane, Dongyuan Xing, Yukinori Minoshima, Richard S. Finn

Analysis of serum biomarkers (BM) in patients (pts) from a phase 3 study of lenvatinib (LEN) vs sorafenib (SOR) as first-line treatment for unresectable hepatocellular carcinoma (uHCC)

Discussion(0)

Related publications

Phase III trial of lenvatinib (LEN) vs sorafenib (SOR) in first-line treatment of patients (pts) with unresectable hepatocellular carcinoma (uHCC).

Final analysis of serum biomarkers in patients (pts) from the phase III study of lenvatinib (LEN) vs sorafenib (SOR) in unresectable hepatocellular carcinoma (uHCC) [REFLECT]

Nivolumab (NIVO) plus ipilimumab (IPI) vs lenvatinib (LEN) or sorafenib (SOR) as first-line treatment for unresectable hepatocellular carcinoma (uHCC): First results from CheckMate 9DW.

Independent imaging review (IIR) results in a phase 3 trial of lenvatinib (LEN) versus sorafenib (SOR) in first-line treatment of patients (pts) with unresectable hepatocellular carcinoma (uHCC).

ctDNA analysis of patients (pts) with unresectable hepatocellular carcinoma (uHCC) treated with lenvatinib (LEN) or sorafenib (SOR) as 1L therapy.